Black Diamond Therapeutics, Inc.
BDTXBlack Diamond Therapeutics, Inc. in brief
Black Diamond Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. Its market value was $108 M on 26 October 2026, which makes it the 18,458th largest listed company in the world and the 3,482nd largest in the USA on this site. In the year to December 2025 it had sales of $70 M and a net profit of $22 M, about 32 cents of profit for every dollar of sales. It employs about 31 people and Mark A. Velleca is its chief executive. Its largest business segments by sales in 2025 were Reportable segment (100%). Its shares trade under the symbol BDTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics is a Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule and Tumor Agnostic Therapies. The company annual revenue is 154.7 million USD and 58 employees as on 2019. The headquarters is in USA.
Black Diamond Therapeutics, Inc. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- ✎Renamed Black Diamond Therapeutics, Inc.Formerly Aset Therapeutics, Inc..
- 2020
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 30 January 2020; shares registered for exchange trading on 27 January 2020.
Events of Black Diamond Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,041 (Jan 2021) · #3,909 (Jan 2022) · #4,836 (Dec 2022) · #3,672 (Jul 2023) · #3,476 (Jan 2024) · #1,879 (Mar 2026) · #3,360 (Aug 2026) · #3,504 (Oct 2026) · #3,485 (Oct 2026)
Key ratios
- P/E ratio
- 4.8×
- Price / sales
- 1.5×
- Price / book
- 1.0×
- Free cash flow yield
- -57.7%
- Net margin
- 32.0%
- Operating margin
- 17.9%
- Return on equity
- 19.9%
- Liabilities / assets
- 21.5%
- R&D / revenue
- 47.9%
- Revenue per employee
- $2.3 M
- Profit per employee
- $722 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $70M | — | $13M | $22M | 32.0% |
| Dec 2024 | — | — | $-79M | $-70M | — |
| Dec 2023 | — | — | $-86M | $-82M | — |
| Dec 2022 | — | — | $-93M | $-91M | — |
| Dec 2021 | — | — | $-127M | $-126M | — |
| Dec 2020 | — | — | $-70M | $-67M | — |
| Dec 2019 | — | — | $-29M | $-35M | — |
| Dec 2018 | — | — | $-9M | $-9M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $30M | — | — | $0.39 | — |
| Dec 2024 | $-62M | $0M | $-62M | $-1.27 | — |
| Dec 2023 | $-67M | $0M | $-67M | $-1.88 | — |
| Dec 2022 | $-85M | $0M | $-85M | $-2.52 | — |
| Dec 2021 | $-100M | $3M | $-103M | $-3.47 | — |
| Dec 2020 | $-52M | $0M | $-52M | $-2.05 | — |
| Dec 2019 | $-25M | $0M | $-25M | $-16.99 | — |
| Dec 2018 | $-8M | $0M | $-9M | $-4.42 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-10M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jun 29, 20268-KCurrent reportShareholder vote
- May 21, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 29, 2026DEF 14AProxy statement
- Mar 16, 202610-KAnnual report · period to Dec 2025
- Mar 16, 20268-KCurrent reportResults of operations
- Dec 3, 20258-KCurrent reportResults of operations · Regulation FD disclosure · Other events
Official filings of Black Diamond Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $70 M
- Operating income
- $13 M
- Net income
- $22 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $143 M
- Total liabilities
- $31 M
- Total equity
- $112 M
As of December-2025
Top 100 institutional investors in Black Diamond Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | NEA Management Company, LLC | 4,448,757 | 0 (0.00%) | 7.74% | $8 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 4,300,642 | +383,554 (+9.79%) | 7.48% | $8 M | Nov 13, 2026 |
| 3 | T. Rowe Price Investment Management, Inc. | 3,925,698 | -102,504 (-2.54%) | 6.83% | $7 M | Nov 16, 2026 |
| 4 | Acadian Asset Management LLC | 2,348,651 | 0 (0.00%) | 4.09% | $4 M | Nov 9, 2026 |
| 5 | Vanguard Capital Management LLC | 2,125,270 | 0 (0.00%) | 3.70% | $4 M | Nov 13, 2026 |
| 6 | Bank Of America Corp /de/ | 2,047,829 | +1,634,313 (+395.22%) | 3.56% | $4 M | Nov 16, 2026 |
| 7 | Defilade Capital Management, L.P. | 1,770,948 | +95,949 (+5.73%) | 3.08% | $3 M | Nov 16, 2026 |
| 8 | Renaissance Technologies LLC | 1,652,100 | -310,294 (-15.81%) | 2.87% | $3 M | Nov 12, 2026 |
| 9 | Geode Capital Management, LLC | 1,246,314 | +28,143 (+2.31%) | 2.17% | $2 M | Nov 6, 2026 |
| 10 | Marshall Wace, LLP | 1,176,357 | +279,755 (+31.20%) | 2.05% | $2 M | Nov 13, 2026 |
| 11 | Connor, Clark & Lunn Investment Management Ltd. | 1,122,679 | +29,794 (+2.73%) | 1.95% | $2 M | Nov 10, 2026 |
| 12 | Dimensional Fund Advisors LP | 955,804 | -409,580 (-30.00%) | 1.66% | $2 M | Nov 4, 2026 |
| 13 | State Street Corp | 943,260 | +418,247 (+79.66%) | 1.64% | $2 M | Nov 12, 2026 |
| 14 | AQR Capital Management LLC | 889,633 | New | 1.55% | $2 M | Nov 16, 2026 |
| 15 | Morgan Stanley | 776,947 | +545,747 (+236.05%) | 1.35% | $1 M | Nov 13, 2026 |
| 16 | FMR LLC | 746,339 | +102,671 (+15.95%) | 1.30% | $1 M | Nov 10, 2026 |
| 17 | Bridgeway Capital Management, LLC | 735,304 | -56,130 (-7.09%) | 1.28% | $1 M | Nov 16, 2026 |
| 18 | Goldman Sachs Group Inc | 687,545 | +398,765 (+138.09%) | 1.20% | $1 M | Nov 16, 2026 |
| 19 | AWM Investment Company, Inc. | 650,000 | -350,000 (-35.00%) | 1.13% | $1 M | Nov 13, 2026 |
| 20 | Vanguard Portfolio Management LLC | 414,847 | +7,773 (+1.91%) | 0.72% | $1 M | Nov 13, 2026 |
| 21 | Northern Trust Corp | 361,550 | -3,844 (-1.05%) | 0.63% | $1 M | Nov 16, 2026 |
| 22 | Empowered Funds, LLC | 358,809 | +110,675 (+44.60%) | 0.62% | $1 M | Nov 13, 2026 |
| 23 | UBS Group AG | 345,978 | +80,665 (+30.40%) | 0.60% | $1 M | Nov 10, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 340,603 | +30,750 (+9.92%) | 0.59% | $1 M | Nov 13, 2026 |
| 25 | Bank of New York Mellon Corp | 308,012 | -10,751 (-3.37%) | 0.54% | $1 M | Nov 5, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Stifel Financial Corp | 289,425 | +8,180 (+2.91%) | 0.50% | $1 M | Nov 12, 2026 |
| 27 | D. E. Shaw & Co., Inc. | 278,469 | +121,129 (+76.99%) | 0.48% | $1 M | Nov 16, 2026 |
| 28 | O'shaughnessy Asset Management, LLC | 166,552 | -122,319 (-42.34%) | 0.29% | $0 M | Nov 12, 2026 |
| 29 | Banque Cantonale Vaudoise | 147,221 | New | 0.26% | $0 M | Nov 12, 2026 |
| 30 | Barclays PLC | 143,991 | +103,934 (+259.47%) | 0.25% | $0 M | Nov 6, 2026 |
| 31 | Charles Schwab Investment Management Inc | 128,418 | +20,730 (+19.25%) | 0.22% | $0 M | Nov 16, 2026 |
| 32 | Panagora Asset Management Inc | 124,496 | -170,676 (-57.82%) | 0.22% | $0 M | Nov 12, 2026 |
| 33 | XTX Topco Ltd | 112,429 | +68,128 (+153.78%) | 0.20% | $0 M | Nov 16, 2026 |
| 34 | BNP Paribas Financial Markets | 106,929 | +98,902 (+1232.12%) | 0.19% | $0 M | Nov 12, 2026 |
| 35 | Canada Pension Plan Investment Board | 103,600 | 0 (0.00%) | 0.18% | $0 M | Nov 16, 2026 |
| 36 | RB Capital Management, LLC | 100,000 | 0 (0.00%) | 0.17% | $0 M | Nov 17, 2026 |
| 37 | Balyasny Asset Management L.P. | 87,313 | -454,859 (-83.90%) | 0.15% | $0 M | Nov 16, 2026 |
| 38 | Ritholtz Wealth Management | 79,183 | -99,296 (-55.63%) | 0.14% | $0 M | Nov 5, 2026 |
| 39 | American Century Companies Inc | 78,245 | -3,066 (-3.77%) | 0.14% | $0 M | Nov 12, 2026 |
| 40 | Invesco Ltd. | 69,039 | -62,624 (-47.56%) | 0.12% | $0 M | Nov 12, 2026 |
| 41 | Nuveen, LLC | 67,387 | +2,586 (+3.99%) | 0.12% | $0 M | Nov 10, 2026 |
| 42 | Raymond James Financial Inc | 67,061 | +4,826 (+7.75%) | 0.12% | $0 M | Nov 12, 2026 |
| 43 | SEI Investments Co | 58,314 | +18,631 (+46.95%) | 0.10% | $0 M | Nov 10, 2026 |
| 44 | Los Angeles Capital Management LLC | 58,025 | New | 0.10% | $0 M | Nov 12, 2026 |
| 45 | Jane Street Group, LLC | 51,291 | -238,421 (-82.30%) | 0.09% | $0 M | Nov 12, 2026 |
| 46 | Two Sigma Investments, LP | 40,604 | -1,396 (-3.32%) | 0.07% | $0 M | Nov 16, 2026 |
| 47 | Deutsche Bank AG\ | 40,261 | -5,777 (-12.55%) | 0.07% | $0 M | Nov 6, 2026 |
| 48 | Citigroup Inc | 40,133 | +16,997 (+73.47%) | 0.07% | $0 M | Nov 4, 2026 |
| 49 | Price T Rowe Associates Inc /MD/ | 39,276 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 50 | HSBC Holdings PLC | 37,542 | +11,121 (+42.09%) | 0.07% | $0 M | Nov 16, 2026 |
| 51 | Ieq Capital, LLC | 37,491 | New | 0.07% | $0 M | Nov 10, 2026 |
| 52 | Susquehanna International Group, LLP | 36,147 | +1,136 (+3.24%) | 0.06% | $0 M | Nov 16, 2026 |
| 53 | Rhumbline Advisers | 35,383 | -1,412 (-3.84%) | 0.06% | $0 M | Nov 10, 2026 |
| 54 | Alliancebernstein L.P. | 32,340 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 55 | Jpmorgan Chase & Co | 31,683 | +2,441 (+8.35%) | 0.06% | $0 M | Nov 12, 2026 |
| 56 | Kestra Advisory Services, LLC | 31,200 | New | 0.05% | $0 M | Nov 2, 2026 |
| 57 | Public Employees Retirement System Of Ohio | 30,396 | New | 0.05% | $0 M | Nov 16, 2026 |
| 58 | New York State Common Retirement Fund | 30,300 | 0 (0.00%) | 0.05% | $0 M | Nov 17, 2026 |
| 59 | EFG International AG | 27,000 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 60 | Mariner, LLC | 25,718 | New | 0.04% | $0 M | Nov 12, 2026 |
| 61 | Beacon Capital Management, LLC | 25,615 | +10,000 (+64.04%) | 0.04% | $0 M | Oct 23, 2026 |
| 62 | Spark Investment Management LLC | 25,200 | +9,700 (+62.58%) | 0.04% | $0 M | Nov 13, 2026 |
| 63 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 22,871 | +1,139 (+5.24%) | 0.04% | $0 M | Nov 16, 2026 |
| 64 | Police & Firemen's Retirement System of New Jersey | 21,909 | -2,176 (-9.03%) | 0.04% | $0 M | Nov 9, 2026 |
| 65 | Corient Private Wealth LP | 20,232 | New | 0.04% | $0 M | Nov 16, 2026 |
| 66 | DLK Investment Management, LLC | 18,200 | +1,985 (+12.24%) | 0.03% | $0 M | Oct 9, 2026 |
| 67 | Kathmere Capital Management, LLC | 18,149 | +7,901 (+77.10%) | 0.03% | $0 M | Oct 20, 2026 |
| 68 | J. Safra Sarasin Holding AG | 17,145 | +1,645 (+10.61%) | 0.03% | $0 M | Oct 26, 2026 |
| 69 | Mercer Global Advisors Inc /adv | 17,049 | New | 0.03% | $0 M | Nov 16, 2026 |
| 70 | Vanguard Global Advisers, LLC | 15,850 | +183 (+1.17%) | 0.03% | $0 M | Nov 13, 2026 |
| 71 | Quadrature Capital Ltd | 15,419 | -61,287 (-79.90%) | 0.03% | $0 M | Nov 13, 2026 |
| 72 | Gsa Capital Partners LLP | 14,820 | -206,087 (-93.29%) | 0.03% | $0 M | Nov 16, 2026 |
| 73 | LPL Financial LLC | 14,705 | -26,090 (-63.95%) | 0.03% | $0 M | Nov 6, 2026 |
| 74 | Creative Planning | 11,329 | New | 0.02% | $0 M | Nov 2, 2026 |
| 75 | China Universal Asset Management Co., Ltd. | 10,483 | +1,363 (+14.95%) | 0.02% | $0 M | Oct 28, 2026 |
| 76 | Wells Fargo & Company/mn | 9,177 | -30,378 (-76.80%) | 0.02% | $0 M | Nov 16, 2026 |
| 77 | Tower Research Capital LLC (TRC) | 7,254 | -2,693 (-27.07%) | 0.01% | $0 M | Nov 16, 2026 |
| 78 | Nisa Investment Advisors, LLC | 4,992 | 0 (0.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 79 | Legal & General Group Plc | 4,564 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 80 | Ameritas Investment Partners, Inc. | 4,283 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 81 | Russell Investments Group, Ltd. | 4,024 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 82 | NewEdge Advisors, LLC | 3,500 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 83 | Mirae Asset Global Investments Co., Ltd. | 2,936 | +373 (+14.55%) | 0.01% | $0 M | Oct 29, 2026 |
| 84 | Royal Bank Of Canada | 2,453 | +953 (+63.53%) | 0.00% | $0 M | Nov 16, 2026 |
| 85 | Allworth Financial LP | 2,151 | New | 0.00% | $0 M | Nov 17, 2026 |
| 86 | Parkside Financial Bank & Trust | 2,112 | New | 0.00% | $0 M | Oct 27, 2026 |
| 87 | Arax Advisory Partners | 2,029 | +2,020 (+22444.44%) | 0.00% | $0 M | Nov 12, 2026 |
| 88 | Optiver Holding B.V. | 1,959 | -5,579 (-74.01%) | 0.00% | $0 M | Nov 16, 2026 |
| 89 | GF Fund Management Co. LTD. | 1,290 | +105 (+8.86%) | 0.00% | $0 M | Oct 26, 2026 |
| 90 | GAMMA Investing LLC | 1,227 | New | 0.00% | $0 M | Oct 8, 2026 |
| 91 | Federated Hermes, Inc. | 1,096 | -2,207 (-66.82%) | 0.00% | $0 M | Nov 12, 2026 |
| 92 | Sterling Capital Management LLC | 901 | -50 (-5.26%) | 0.00% | $0 M | Oct 22, 2026 |
| 93 | SJS Investment Consulting Inc. | 882 | New | 0.00% | $0 M | Oct 26, 2026 |
| 94 | Global Retirement Partners, LLC | 677 | New | 0.00% | $0 M | Nov 10, 2026 |
| 95 | Osaic Holdings, Inc. | 480 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 96 | Farther Finance Advisors, LLC | 430 | New | 0.00% | $0 M | Oct 8, 2026 |
| 97 | Jones Financial Companies Lllp | 428 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 98 | EverSource Wealth Advisors, LLC | 366 | New | 0.00% | $0 M | Nov 4, 2026 |
| 99 | Rothschild Investment LLC | 325 | New | 0.00% | $0 M | Nov 10, 2026 |
| 100 | Federation des caisses Desjardins du Quebec | 280 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding Black Diamond Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 2.12 M | $4 M | 3.7% | 0.04% | −0.5% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.56 M | $3 M | 2.7% | <0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.21 M | $2 M | 2.1% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 521,043 | $1 M | 0.91% | 0.02% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 511,250 | $1 M | 0.89% | <0.01% | +3.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 513,120 | $1 M | 0.89% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 465,655 | $1 M | 0.81% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 469,215 | $1 M | 0.82% | 0.02% | +118% | Jul 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 347,116 | $1 M | 0.60% | <0.01% | +8.0% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Value PortfolioDimensional Fund Advisors LP | 341,219 | $1 M | 0.59% | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 240,495 | $1 M | 0.42% | <0.01% | +0.8% | May 31, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 248,134 | $0 M | 0.43% | 0.02% | +7.8% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Small Cap Value ETFDimensional Fund Advisors LP | 210,208 | $0 M | 0.37% | <0.01% | +31% | Jul 31, 2026 |
| 🇺🇸 Small Cap Value PortfolioMason Street Advisors, LLC | 182,571 | $0 M | 0.32% | 0.05% | −9.4% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 159,482 | $0 M | 0.28% | 0.02% | +35% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc. | 96,029 | $0 M | 0.17% | <0.01% | +2.3% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 113,822 | $0 M | 0.20% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 78,981 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 93,180 | $0 M | 0.16% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 73,654 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 88,223 | $0 M | 0.15% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 88,000 | $0 M | 0.15% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 94,181 | $0 M | 0.16% | <0.01% | −9.4% | Jul 31, 2026 |
| 🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc. | 85,380 | $0 M | 0.15% | 0.02% | −2.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 67,272 | $0 M | 0.12% | <0.01% | +6.4% | May 31, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 70,000 | $0 M | 0.12% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 74,316 | $0 M | 0.13% | <0.01% | −61% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 65,660 | $0 M | 0.11% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 69,382 | $0 M | 0.12% | <0.01% | −1.1% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 64,801 | $0 M | 0.11% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 62,435 | $0 M | 0.11% | <0.01% | −67% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 53,319 | $0 M | 0.09% | 0.01% | −38% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 52,616 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Company Value TrustJohn Hancock Variable Trust Advisers LLC | 40,600 | $0 M | 0.07% | 0.05% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 32,498 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 38,400 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc. | 31,074 | $0 M | 0.05% | <0.01% | −12% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 35,761 | $0 M | 0.06% | <0.01% | −48% | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 30,769 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 27,000 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc. | 21,171 | $0 M | 0.04% | <0.01% | −8.9% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 21,836 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 23,643 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 22,531 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 20,201 | $0 M | 0.04% | <0.01% | −34% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 16,658 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 16,170 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 16,170 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust | 12,801 | $0 M | 0.02% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 15,807 | $0 M | 0.03% | <0.01% | −1.1% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 14,484 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 11,160 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 11,008 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,787 | $0 M | 0.02% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 10,772 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 9,304 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 7,818 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 7,701 | $0 M | 0.01% | <0.01% | −22% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 7,559 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 8,280 | $0 M | 0.01% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 7,305 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 7,200 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 4,591 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 5,527 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 5,320 | $0 M | <0.01% | <0.01% | +3.9% | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 5,128 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 4,590 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,283 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,774 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 3,559 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 3,843 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,390 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 3,325 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 1,700 | $0 M | <0.01% | <0.01% | +325% | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 2,000 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 1,828 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,613 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,136 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,090 | $0 M | <0.01% | <0.01% | −6.1% | Jun 30, 2026 |
| 🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 968 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 298 | $0 M | <0.01% | <0.01% | +32% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 81 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Black Diamond Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Prakash RamanDirector | Grant or award | +6,801 | $1.930 | $13 K | 51,840 | Form 4 |
| filed | Ali BehbahaniDirector | Grant or award | +7,707 | $1.930 | $15 K | 110,236 | Form 4 |
| filed | Ali BehbahaniDirector | Grant or award | +8,961 | $1.660 | $15 K | 102,529 | Form 4 |
| filed | Prakash RamanDirector | Grant or award | +7,907 | $1.660 | $13 K | 45,039 | Form 4 |
| filed | Ali BehbahaniDirector | Grant or award | +6,919 | $2.150 | $15 K | 93,568 | Form 4 |
| filed | Prakash RamanDirector | Grant or award | +6,105 | $2.150 | $13 K | 37,132 | Form 4 |
| filed | Ali BehbahaniDirector | Grant or award | +5,208 | $2.760 | $14 K | 86,649 | Form 4 |
| filed | Prakash RamanDirector | Grant or award | +4,665 | $2.760 | $13 K | 31,027 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Black Diamond Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 3.016-for-1 split
Trading halts
- 2025-12-03 14:33 UTC, code LUDP, resumed 14:43 UTC
Fails to deliver
- : 12,177 shares at $1.88
- : 4,385 shares at $2.08
- : 2,795 shares at $1.68
- : 7,117 shares at $1.94
- : 934 shares at $1.87
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Black Diamond Therapeutics, Inc. scorecard#
Passes 10 of the 15 checks that could be worked out: strongest in valuation (4 of 5), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation4 of 5
- ✓P/E below its peers' median4.8×P/E 4.8× against Biotechnology's median of 17.5×.
- ✓Price to book below its peers' median1.0×Price to book 1.0× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.5×Price to sales 1.5× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-57.7%Free cash flow is -57.7% of the market value.
- ✓Earnings yield above the 10-year Treasury yield20.7%Earnings yield 20.7% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year0.39 vs -1.27Diluted EPS 0.39 in fiscal 2025 against -1.27 the year before (report's currency).
- ✓Net income higher than five years earlier$22 M$22 M in fiscal 2025 against -$67 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability3 of 4
- ✓Profitable in the newest year$22 MNet income $22 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median17.9%17.9% against Biotechnology's median of -60.5% (243 companies).
- ✓Return on equity above 15%22.9%22.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities8.4×Current ratio 8.42 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.69Z-score -0.69 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.6%Diluted shares up 4.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Black Diamond Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 17.9% | -60.5% | |
| Net margin | 32.0% | -68.9% | |
| Return on equity | 22.9% | -61.0% |
5of 6on the Piotroski tests of financial strength
Black Diamond Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 70—100% | 0—— | — | — | — | 0—— | 0—— | 0—— | |
| Research and development | 34−34.6%47.9% | 51−13.5%— | 59−7.9%— | 64−33.5%— | 97+101%— | 48+122%— | 22+213%— | 7.0—— | |
| General and administrative | 17−39.7%23.7% | 27+1.3%— | 27−4.5%— | 28−5.5%— | 30+40.6%— | 21+182%— | 7.6+288%— | 2.0—— | |
| Operating expenses | 57−27.0%82.1% | 79−8.9%— | 86−6.9%— | 93−26.8%— | 127+82.4%— | 70+137%— | 29+229%— | 8.9—— | |
| Operating income | 13—17.9% | −79—— | −86—— | −93—— | −127—— | −70—— | −29—— | −8.9—— | |
| Interest expense and finance costs | — | — | — | — | 0−100%— | 0.0—— | 0—— | — | |
| Share of profit of associates | — | — | 0—— | −2.3—— | 0—— | — | — | — | |
| Other non-operating income (expense) | 9.8+8.1%14.1% | 9.1+127%— | 4.0+2.8%— | 3.9+206%— | 1.3−44.9%— | 2.3—— | −5.9—— | −0.0—— | |
| Income tax | 0—0.0% | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income attributable to shareholders | 22—32.0% | −70—— | −82—— | −91—— | −126—— | −67—— | −35—— | −8.9—— | |
| Earnings per share, basic | 0.39—— | -1.27—— | -1.88—— | -2.52—— | -3.47—— | -2.05—— | -16.99—— | -4.42—— | |
| Earnings per share, diluted | 0.39—— | -1.27—— | -1.88—— | -2.52—— | -3.47—— | -2.05—— | -16.99—— | -4.42—— | |
| Shares, weighted average (basic) | 57+3.3%— | 55+25.2%— | 44+21.0%— | 36+0.4%— | 36+10.0%— | 33—— | — | — | |
| Shares, weighted average (diluted) | 58+4.6%— | 55+25.2%— | 44+21.0%— | 36+0.4%— | 36+10.0%— | 33+1485%— | 2.1+2.8%— | 2.0—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 21−42.4%14.7% | 36−35.2%29.7% | 56+63.8%35.5% | 34−47.8%22.0% | 66+90.1%26.6% | 35−77.6%10.5% | 155+199%97.7% | 52—99.7% | |
| Short-term investments | 108+73.3%75.3% | 62−17.3%50.7% | 75−15.0%47.4% | 88−38.5%56.6% | 144−48.7%58.1% | 280—85.1% | 0—0.0% | — | |
| Other current assets | 3.8+45.6%2.6% | 2.6−1.3%2.1% | 2.6−46.2%1.7% | 4.9−17.2%3.1% | 5.9+31.9%2.4% | 4.5+328%1.4% | 1.0+4267%0.7% | 0.0—0.0% | |
| Current assets | 132+30.9%92.6% | 101−24.5%82.5% | 134+5.0%84.5% | 128−40.8%81.7% | 216−32.5%87.1% | 320+105%96.9% | 156+201%98.4% | 52—99.7% | |
| Property, plant and equipment | 0.4−73.7%0.3% | 1.4−19.8%1.1% | 1.7−33.1%1.1% | 2.6−14.8%1.7% | 3.0+688%1.2% | 0.4+135%0.1% | 0.2+22.4%0.1% | 0.1—0.3% | |
| Right-of-use (leased) assets | 9.3−51.1%6.5% | 19−13.5%15.5% | 22−11.3%13.9% | 25−10.5%15.9% | 28+230%11.2% | 8.4—2.5% | — | — | |
| Total assets | 143+16.6%100% | 123−22.7%100% | 159+1.5%100% | 156−36.9%100% | 248−24.9%100% | 330+108%100% | 158+205%100% | 52—100% | |
| Accounts payable | 0.6−85.6%0.4% | 4.0+72.4%3.3% | 2.3+23.8%1.5% | 1.9−54.3%1.2% | 4.1+61.8%1.7% | 2.5+29.2%0.8% | 2.0+372%1.2% | 0.4—0.8% | |
| Current liabilities | 16−23.5%11.0% | 21+4.7%16.8% | 20+28.7%12.4% | 15−35.4%9.8% | 24+66.3%9.5% | 14+192%4.3% | 4.9+88.9%3.1% | 2.6—5.0% | |
| Lease liabilities (non-current) | 15−19.8%10.5% | 19−15.3%15.3% | 22−12.3%14.0% | 25−10.1%16.2% | 28+266%11.4% | 7.7—2.3% | — | — | |
| Total liabilities | 31−21.7%21.5% | 39−5.9%32.1% | 42+3.1%26.4% | 41−21.7%26.0% | 52+136%20.9% | 22+349%6.6% | 4.9−26.1%3.1% | 6.6—12.7% | |
| Retained earnings | −465—−325% | −487—−397% | −417—−263% | −335—−214% | −244—−98.4% | −118—−35.9% | −51—−32.2% | −16—−30.3% | |
| Shareholders' equity | 112+34.7%78.5% | 83−28.7%67.9% | 117+0.9%73.6% | 116−40.9%74.0% | 196−36.3%79.1% | 308—93.4% | −47—−29.8% | −16—−30.0% | |
| Total liabilities and equity | 143+16.6%100% | 123−22.7%100% | 159+1.5%100% | 156−36.9%100% | 248−24.9%100% | 330+108%100% | 158+205%100% | 52—100% | |
| Shares outstanding | 57+0.9%— | 57+9.7%— | 52+41.7%— | 36+0.6%— | 36+0.4%— | 36+1513%— | 2.2+2.9%— | 2.2—— | |
| Cash-flow statement | |||||||||
| Share-based compensation | 6.6−37.6%9.5% | 11+10.7%— | 9.6−21.3%— | 12−13.1%— | 14+80.8%— | 7.8+113%— | 3.6+5592%— | 0.1—— | |
| Cash from operating activities | 30—42.3% | −62—— | −67—— | −85—— | −100—— | −52—— | −25—— | −8.5—— | |
| Capital expenditure | — | 0—— | −0.0—— | −0.2—— | −2.7—— | −0.1—— | −0.0—— | −0.1—— | |
| Cash from investing activities | −45−365%−64.1% | 17+3.8%— | 16−69.4%— | 53−59.1%— | 131—— | −282—— | −0.0—— | −0.1—— | |
| Shares issued | 0−100%0.0% | 24−65.9%— | 72—— | 0—— | — | — | — | — | |
| Cash from financing activities | −0.1−101%−0.2% | 26−64.5%— | 72+40540%— | 0.2−75.7%— | 0.7−99.7%— | 215+68.2%— | 128+144%— | 52—— | |
| Change in cash | −15—−22.1% | −20−192%— | 22—— | −32−201%— | 31—— | −119−215%— | 103+135%— | 44—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0−100%— | 0—— | 0—— | 0−100%— | 0*—— | 0—— | 0—— | 70—100% | 0*—— | 0—— | 0—— | 0—— | — | |
| Research and development | 28−30.1%— | 7.0−6.2%— | 7.4−20.7%— | 7.0−33.3%— | 6.3*−48.8%— | 7.4−42.4%— | 9.3−25.8%— | 11−22.4%15.0% | 12*−19.6%— | 13—— | 13—— | 14—— | 15*—— | |
| General and administrative | 18−3.0%— | 5.1+45.4%— | 4.7+13.7%— | 4.3−14.3%— | 4.0*−33.7%— | 3.5−32.1%— | 4.1−57.2%— | 5.0−25.9%7.1% | 6.0*+7.4%— | 5.2—— | 9.6—— | 6.7—— | 5.6*—— | |
| Operating expenses | 53−8.8%— | 12+10.4%— | 12−10.2%— | 11−27.2%— | 18*−3.6%— | 11−39.4%— | 13−39.4%— | 15−23.6%22.1% | 18*−12.4%— | 18—— | 22—— | 20—— | 21*—— | |
| Operating income | −53−547%— | −12—— | −12—— | −11−121%— | −18*—— | −11—— | −13—— | 55—77.9% | −18*—— | −18—— | −22—— | −20—— | −21*—— | |
| Other non-operating income (expense) | 9.0−6.9%— | 2.1−14.9%— | 2.2−24.7%— | 2.2+10.5%— | 2.5*+8.9%— | 2.5−3.6%— | 2.9+28.7%— | 2.0−0.4%2.9% | 2.3*+58.3%— | 2.6—— | 2.2—— | 2.0—— | 1.4*—— | |
| Income tax | — | — | — | — | — | — | 0*—— | 0.2—0.3% | — | — | — | — | — | |
| Net income attributable to shareholders | −44−305%— | −10—— | −9.9—— | −9.0−116%— | −15*—— | −8.5—— | −11—— | 57—80.8% | −16*—— | −16—— | −20—— | −18—— | −19*—— | |
| Earnings per share, basic | — | -0.17—— | -0.17—— | -0.16−116%— | — | -0.15—— | -0.19—— | 1.00—— | — | -0.28—— | -0.36—— | -0.35—— | — | |
| Earnings per share, diluted | — | -0.17—— | -0.17—— | -0.16−116%— | — | -0.15—— | -0.19—— | 0.98—— | — | -0.28—— | -0.36—— | -0.35—— | — | |
| Shares, weighted average (basic) | 57+0.9%— | 57+0.9%— | 57+1.0%— | 57+1.0%— | — | 57+0.7%— | 57+3.0%— | 57+9.4%— | — | 57—— | 55—— | 52—— | — | |
| Shares, weighted average (diluted) | 57+0.9%— | 57+0.9%— | 57+1.0%— | 57−0.8%— | — | 57+0.7%— | 57+3.0%— | 58+11.3%— | — | 57—— | 55—— | 52—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 15—13.1% | 15−51.1%13.1% | 19−36.0%15.4% | 30−69.4%22.6% | 21−42.4%14.7% | 31+31.8%19.6% | 30−8.6%18.0% | 98+287%55.8% | 36−35.2%29.7% | 23—17.0% | 33—21.9% | 25—17.8% | 56—35.5% | |
| Short-term investments | 87—75.2% | 87−16.9%75.2% | 91−19.1%73.0% | 88+63.4%66.3% | 108+73.3%75.3% | 105+17.2%66.3% | 113+25.2%67.8% | 54−39.9%30.6% | 62−17.3%50.7% | 89—64.7% | 90—60.1% | 90—63.0% | 75—47.4% | |
| Other current assets | 4.5—3.9% | 4.5+29.3%3.9% | 4.9+25.4%3.9% | 4.7+43.6%3.5% | 3.8+45.6%2.6% | 3.5+22.2%2.2% | 3.9+3.0%2.3% | 3.3−9.1%1.9% | 2.6−1.3%2.1% | 2.9—2.1% | 3.8—2.5% | 3.6—2.5% | 2.6—1.7% | |
| Current assets | 107—92.2% | 107−23.3%92.2% | 115−21.4%92.3% | 123−21.0%92.5% | 132+30.9%92.6% | 139+20.3%88.1% | 147+15.8%88.2% | 156+31.0%88.3% | 101−24.5%82.5% | 116—83.8% | 127—84.5% | 119—83.4% | 134—84.5% | |
| Property, plant and equipment | 0.3—0.2% | 0.3−75.0%0.2% | 0.3−74.5%0.2% | 0.3−74.0%0.3% | 0.4−73.7%0.3% | 1.1−23.4%0.7% | 1.2−22.1%0.7% | 1.3−20.9%0.7% | 1.4−19.8%1.1% | 1.5—1.1% | 1.6—1.0% | 1.6—1.2% | 1.7—1.1% | |
| Right-of-use (leased) assets | 7.7—6.6% | 7.7−54.1%6.6% | 8.2−53.0%6.6% | 8.8−52.0%6.6% | 9.3−51.1%6.5% | 17−15.7%10.6% | 17−14.9%10.5% | 18−14.2%10.3% | 19−13.5%15.5% | 20—14.3% | 21—13.7% | 21—14.9% | 22—13.9% | |
| Total assets | 116—100% | 116−26.7%100% | 125−24.9%100% | 133−24.6%100% | 143+16.6%100% | 158+14.4%100% | 166+10.9%100% | 176+23.7%100% | 123−22.7%100% | 138—100% | 150—100% | 143—100% | 159—100% | |
| Accounts payable | 1.0—0.9% | 1.0+6.8%0.9% | 1.4+82.1%1.1% | 3.0+13.0%2.2% | 0.6−85.6%0.4% | 1.0−50.5%0.6% | 0.8+1.0%0.5% | 2.6+123%1.5% | 4.0+72.4%3.3% | 2.0—1.4% | 0.8—0.5% | 1.2—0.8% | 2.3—1.5% | |
| Current liabilities | 15—13.3% | 15−0.9%13.3% | 16−5.7%12.7% | 15−13.7%10.9% | 16−23.5%11.0% | 16−25.3%9.9% | 17−8.9%10.1% | 17−0.0%9.6% | 21+4.7%16.8% | 21—15.1% | 18—12.3% | 17—11.8% | 20—12.4% | |
| Lease liabilities (non-current) | 12—10.5% | 12−24.7%10.5% | 13−22.8%10.5% | 14−21.2%10.6% | 15−19.8%10.5% | 16−18.5%10.2% | 17−17.3%10.2% | 18−16.3%10.1% | 19−15.3%15.3% | 20—14.3% | 21—13.7% | 21—15.0% | 22—14.0% | |
| Total liabilities | 27—23.8% | 27−13.0%23.8% | 29−14.3%23.1% | 29−17.6%21.5% | 31−21.7%21.5% | 32−22.0%20.0% | 34−13.3%20.3% | 35−9.1%19.7% | 39−5.9%32.1% | 40—29.3% | 39—26.0% | 38—26.8% | 42—26.4% | |
| Retained earnings | −494—−427% | −494—−427% | −484—−387% | −474—−356% | −465—−325% | −450—−285% | −441—−265% | −431—−244% | −487—−397% | −471—−342% | −456—−304% | −436—−306% | −417—−263% | |
| Shareholders' equity | 88—76.2% | 88−30.2%76.2% | 96−27.5%76.9% | 104−26.3%78.5% | 112+34.7%78.5% | 126+29.5%80.0% | 133+20.0%79.7% | 142+35.7%80.3% | 83−28.7%67.9% | 97—70.7% | 111r111—73.7% | 104—73.2% | 117—73.6% | |
| Total liabilities and equity | 116—100% | 116−26.7%100% | 125−24.9%100% | 133−24.6%100% | 143+16.6%100% | 158+14.4%100% | 166+10.9%100% | 176+23.7%100% | 123−22.7%100% | 138—100% | 150—100% | 143—100% | 159—100% | |
| Shares outstanding | 57—— | 57+0.9%— | 57+1.0%— | 57+1.1%— | 57+0.9%— | 57+0.7%— | 57+0.8%— | 57+7.9%— | 57+9.7%— | 57—— | 56—— | 53—— | 52—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 6.6−3.7%— | 2.2+28.1%— | 1.5−15.0%— | 1.4−14.9%— | 1.4*−13.7%— | 1.7−12.7%— | 1.8−66.4%— | 1.7−0.8%2.4% | 1.6*+6.5%— | 2.0—— | 5.3—— | 1.7—— | 1.5*—— | |
| Cash from operating activities | −33−256%— | −8.3*—— | −8.0*—— | −10−119%— | −6.8*—— | −7.9*—— | −9.2*—— | 53—76.3% | −15*—— | −11*—— | −15*—— | −21—— | −14*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | 0*—— | — | — | — | 0*—— | |
| Cash from investing activities | 18—— | 4.2*−50.9%— | −3.1*—— | 20+128%— | −2.9*−110%— | 8.6*+292%— | −59*−8094%— | 8.5—12.2% | 28*+127%— | 2.2*—— | 0.7*—— | −14—— | 12*—— | |
| Shares issued | — | — | — | — | 0*—— | 0*—— | 0*−100%— | 0−100%0.0% | 0*—— | −0.5*—— | 21*—— | 4.0—— | 0*—— | |
| Cash from financing activities | −0.2−145%— | 0.0*−91.0%— | 0.2*—— | −0.2−678%— | −0.2*−167%— | 0.1*—— | −0.1*−101%— | 0.0−99.2%0.0% | 0.3*—— | −0.3*—— | 21*—— | 4.1—— | −0.0*—— | |
| Change in cash | −16−312%— | −4.1*−570%— | −11*—— | 9.1−85.3%— | −9.9*−176%— | 0.9*—— | −68*−1026%— | 62—88.6% | 13*—— | −9.4*—— | 7.4*—— | −31—— | −1.8*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Black Diamond Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable segment$70 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Black Diamond Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Velleca | $2.2 M | $2.6 M | $1.3 M | $89 |
| 2024Mark A. Velleca | $2.9 M | $1.9 M | $1.5 M | $76 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Black Diamond Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Black Diamond Therapeutics, Inc. compares in Biotechnology
- Market cap$108 M · higher than 37% of 726
- Revenue$70 M · higher than 64% of 647
- Net margin32.0% · higher than 92% of 408
- P/E ratio4.8× · lower than 85% of 100
- Price / sales1.5× · lower than 90% of 339
- Price / book1.0× · lower than 80% of 534
- FCF yield-57.7% · higher than 21% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Black Diamond Therapeutics, Inc.🇺🇸 | $108 M | 4.8× | 32.0% | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on January-2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Black Diamond Therapeutics, Inc.? Verify and update this profile — free
Show Black Diamond Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.